Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31588493.
- Also identified by DOI 10.1093/cid/ciz885 and PMC identifier 7201409.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.
Medical subject headings
- Antifungal Agents
- Obesity, Morbid